Stocks · News reference

Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

Aug 3, 2026, 4:00 PMBenzinga Newsdesk

Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Zacks Investment ResearchSep 3, 2026, 12:41 PMNa
Bet on 5 Top-Ranked Stocks With Rising P/E
The article explores how rising P/E ratios, combined with accelerating earnings growth and sustained price momentum, can indicate strong investment opportunities. Five stocks meeting these criteria are highlighted: CuriosityStream (CURI), Inovio Pharmaceuticals (INO), GDS Holdings (GDS), Nouveau Monde Graphite (NMG), and Cogent Communications (CCOI). These companies demonstrate consistent price gains relative to the S&P 500 and positive earnings trends.
CURI INO GDS NMG CCOI
BenzingaAug 28, 2026, 4:43 PMBenzinga Newsdesk
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
CODX EBS GILD GOVX INO
BenzingaAug 13, 2026, 4:43 PMBenzinga Newsdesk
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3
Jefferies analyst Roger Song upgrades Inovio Pharmaceuticals (NASDAQ:INO) from Hold to Buy and raises the price target from $1.8 to $3.
INO
BenzingaAug 13, 2026, 4:04 PMBenzinga Newsdesk
Inovio Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS results.
INO